Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Mechanisms of Spindle Positioning: Lessons from Worms and Mammalian Cells.

Kotak S.

Biomolecules. 2019 Feb 25;9(2). pii: E80. doi: 10.3390/biom9020080. Review.

2.

Mitotic Spindle: Illuminating Spindle Positioning with a Biological Lightsaber.

Kotak S.

Curr Biol. 2018 Nov 19;28(22):R1308-R1310. doi: 10.1016/j.cub.2018.09.047. Epub 2018 Nov 19.

PMID:
30458151
3.

Plk1 regulates spindle orientation by phosphorylating NuMA in human cells.

Sana S, Keshri R, Rajeevan A, Kapoor S, Kotak S.

Life Sci Alliance. 2018 Nov 16;1(6):e201800223. doi: 10.26508/lsa.201800223. eCollection 2018 Dec.

4.

Maintenance of remission with combination etanercept-DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access.

Pavelka K, Akkoç N, Al-Maini M, Zerbini CAF, Karateev DE, Nasonov EL, Rahman MU, Pedersen R, Dinh A, Shen Q, Vasilescu R, Kotak S, Mahgoub E, Vlahos B.

Rheumatol Int. 2017 Sep;37(9):1469-1479. doi: 10.1007/s00296-017-3749-7. Epub 2017 Jun 9.

PMID:
28597306
5.

Correction: The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study.

Moots RJ, Xavier RM, Mok CC, Rahman MU, Tsai WC, Al-Maini MH, Pavelka K, Mahgoub E, Kotak S, Korth-Bradley J, Pedersen R, Mele L, Shen Q, Vlahos B.

PLoS One. 2017 Jun 5;12(6):e0179308. doi: 10.1371/journal.pone.0179308. eCollection 2017.

6.

Clinical and demographic factors associated with change and maintenance of disease severity in a large registry of patients with rheumatoid arthritis.

Reed GW, Collier DH, Koenig AS, Saunders KC, Pappas DA, Litman HJ, Kremer JM, Kotak S.

Arthritis Res Ther. 2017 Apr 27;19(1):81. doi: 10.1186/s13075-017-1289-x.

7.

The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study.

Moots RJ, Xavier RM, Mok CC, Rahman MU, Tsai WC, Al-Maini MH, Pavelka K, Mahgoub E, Kotak S, Korth-Bradley J, Pedersen R, Mele L, Shen Q, Vlahos B.

PLoS One. 2017 Apr 27;12(4):e0175207. doi: 10.1371/journal.pone.0175207. eCollection 2017. Erratum in: PLoS One. 2017 Jun 5;12 (6):e0179308.

8.

Dr. Wiland, et al, reply.

Wiland P, Dudler J, Veale D, Tahir H, Pedersen R, Bukowski J, Vlahos B, Williams T, Gaylord S, Kotak S.

J Rheumatol. 2017 Feb;44(2):259. doi: 10.3899/jrheum.161405. No abstract available.

PMID:
28148758
9.

Efficacy and safety of etanercept in patients from Latin America, Central Europe and Asia with early non-radiographic axial spondyloarthritis.

Wei JC, Tsai WC, Citera G, Kotak S, Llamado L.

Int J Rheum Dis. 2018 Jul;21(7):1443-1451. doi: 10.1111/1756-185X.12973. Epub 2016 Nov 11.

PMID:
27863065
10.

Impact of etanercept tapering on work productivity in patients with early rheumatoid arthritis: results from the PRIZE study.

Zhang W, Bansback N, Sun H, Pedersen R, Kotak S, Anis AH.

RMD Open. 2016 Jul 7;2(2):e000222. doi: 10.1136/rmdopen-2015-000222. eCollection 2016.

11.

Discovery of a Selective Aurora A Kinase Inhibitor by Virtual Screening.

Kilchmann F, Marcaida MJ, Kotak S, Schick T, Boss SD, Awale M, Gönczy P, Reymond JL.

J Med Chem. 2016 Aug 11;59(15):7188-211. doi: 10.1021/acs.jmedchem.6b00709. Epub 2016 Jul 20.

PMID:
27391133
12.

Erratum to: The prevalence and clinical characteristics of nonradiographic axial spondyloarthritis among patients with inflammatory back pain in rheumatology practices: a multinational, multicenter study.

Burgos-Vargas R, Wei JC, Rahman MU, Akkoc N, Haq SA, Hammoudeh M, Mahgoub E, Singh E, Llamado LJ, Shirazy K, Kotak S, Hammond C, Pedersen R, Shen Q, Vlahos B.

Arthritis Res Ther. 2016 Jul 4;18(1):154. No abstract available.

13.

Aurora A kinase regulates proper spindle positioning in C. elegans and in human cells.

Kotak S, Afshar K, Busso C, Gönczy P.

J Cell Sci. 2016 Aug 1;129(15):3015-25. doi: 10.1242/jcs.184416. Epub 2016 Jun 22.

14.

The prevalence and clinical characteristics of nonradiographic axial spondyloarthritis among patients with inflammatory back pain in rheumatology practices: a multinational, multicenter study.

Burgos-Varga R, Wei JC, Rahman MU, Akkoc N, Haq SA, Hammoudeh M, Mahgoub E, Singh E, Llamado LJ, Shirazy K, Kotak S, Hammond C, Pedersen R, Shen Q, Vlahos B.

Arthritis Res Ther. 2016 Jun 7;18(1):132. doi: 10.1186/s13075-016-1027-9. Erratum in: Arthritis Res Ther. 2016;18(1):154.

15.

The Effect of Reduced or Withdrawn Etanercept-methotrexate Therapy on Patient-reported Outcomes in Patients with Early Rheumatoid Arthritis.

Wiland P, Dudler J, Veale D, Tahir H, Pedersen R, Bukowski J, Vlahos B, Williams T, Gaylord S, Kotak S.

J Rheumatol. 2016 Jul;43(7):1268-77. doi: 10.3899/jrheum.151179. Epub 2016 Jun 1.

PMID:
27252426
16.

Discordance between patient and physician assessments of global disease activity in rheumatoid arthritis and association with work productivity.

Smolen JS, Strand V, Koenig AS, Szumski A, Kotak S, Jones TV.

Arthritis Res Ther. 2016 May 21;18(1):114. doi: 10.1186/s13075-016-1004-3.

17.

Two-Year Safety and Efficacy Experience in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis Treated with Etanercept and Conventional Disease-Modifying Anti-rheumatic Drugs in the Latin American Region.

Machado DA, Guzman R, Xavier RM, Simon JA, Mele L, Shen Q, Pedersen R, Kotak S, Vlahos B.

Open Rheumatol J. 2016 Feb 29;10:13-25. doi: 10.2174/1874312901610010013. eCollection 2016.

18.

Assessment of clinical efficacy and safety in a randomized double-blind study of etanercept and sulfasalazine in patients with ankylosing spondylitis from Eastern/Central Europe, Latin America, and Asia.

Damjanov N, Shehhi WA, Huang F, Kotak S, Burgos-Vargas R, Shirazy K, Bananis E, Szumski A, Llamado LJ, Mahgoub E.

Rheumatol Int. 2016 May;36(5):643-51. doi: 10.1007/s00296-016-3452-0. Epub 2016 Mar 11.

PMID:
26968844
19.

Estimating the monetary value of the annual productivity gained in patients with early rheumatoid arthritis receiving etanercept plus methotrexate: interim results from the PRIZE study.

Zhang W, Bansback N, Sun H, Pedersen R, Kotak S, Anis AH.

RMD Open. 2015 Apr 8;1(1):e000042. doi: 10.1136/rmdopen-2014-000042. eCollection 2015.

20.

Impact of Etanercept Therapy on Disease Activity and Health-Related Quality of Life in Moderate Rheumatoid Arthritis Patients Population from a National British Observational Cohort.

Kotak S, Mardekian J, Horowicz-Mehler N, Shah A, Burgess A, Kim J, Gemmen E, Boyd H, Koenig A.

Value Health. 2015 Sep;18(6):817-23. doi: 10.1016/j.jval.2015.05.005. Epub 2015 Jul 22.

21.

Evaluation of Health Outcomes with Etanercept Treatment in Patients with Early Nonradiographic Axial Spondyloarthritis.

Dougados M, Tsai WC, Saaibi DL, Bonin R, Bukowski J, Pedersen R, Vlahos B, Kotak S.

J Rheumatol. 2015 Oct;42(10):1835-41. doi: 10.3899/jrheum.141313. Epub 2015 Aug 15.

PMID:
26276968
22.

Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study.

Maksymowych WP, Dougados M, van der Heijde D, Sieper J, Braun J, Citera G, Van den Bosch F, Logeart I, Wajdula J, Jones H, Marshall L, Bonin R, Pedersen R, Vlahos B, Kotak S, Bukowski JF.

Ann Rheum Dis. 2016 Jul;75(7):1328-35. doi: 10.1136/annrheumdis-2015-207596. Epub 2015 Aug 12.

23.

The burden of non-radiographic axial spondyloarthritis.

Boonen A, Sieper J, van der Heijde D, Dougados M, Bukowski JF, Valluri S, Vlahos B, Kotak S.

Semin Arthritis Rheum. 2015 Apr;44(5):556-562. doi: 10.1016/j.semarthrit.2014.10.009. Epub 2014 Oct 22. Review.

PMID:
25532945
24.

NuMA interacts with phosphoinositides and links the mitotic spindle with the plasma membrane.

Kotak S, Busso C, Gönczy P.

EMBO J. 2014 Aug 18;33(16):1815-30. doi: 10.15252/embj.201488147. Epub 2014 Jul 4.

25.

Open-label observation of addition of etanercept versus a conventional disease-modifying antirheumatic drug in subjects with active rheumatoid arthritis despite methotrexate therapy in the Latin American region.

Machado DA, Guzman RM, Xavier RM, Simon JA, Mele L, Pedersen R, Ferdousi T, Koenig AS, Kotak S, Vlahos B.

J Clin Rheumatol. 2014 Jan;20(1):25-33. doi: 10.1097/RHU.0000000000000055.

PMID:
24356474
26.

NuMA phosphorylation dictates dynein-dependent spindle positioning.

Kotak S, Gönczy P.

Cell Cycle. 2014;13(2):177-8. doi: 10.4161/cc.27040. Epub 2013 Nov 15. No abstract available.

27.

Mechanisms of spindle positioning: cortical force generators in the limelight.

Kotak S, Gönczy P.

Curr Opin Cell Biol. 2013 Dec;25(6):741-8. doi: 10.1016/j.ceb.2013.07.008. Epub 2013 Aug 16. Review.

PMID:
23958212
28.

NuMA phosphorylation by CDK1 couples mitotic progression with cortical dynein function.

Kotak S, Busso C, Gönczy P.

EMBO J. 2013 Sep 11;32(18):2517-29. doi: 10.1038/emboj.2013.172. Epub 2013 Aug 6.

29.

Induction of response with etanercept-methotrexate therapy in patients with moderately active rheumatoid arthritis in Central and Eastern Europe in the PRESERVE study.

Pavelka K, Szekanecz Z, Damjanov N, Majdan M, Nasonov E, Mazurov V, Fabo T, Bananis E, Jones H, Szumski A, Tang B, Kotak S, Koenig AS, Vasilescu R.

Clin Rheumatol. 2013 Sep;32(9):1275-81. doi: 10.1007/s10067-013-2240-4. Epub 2013 May 11.

PMID:
23666316
30.

MISP is a novel Plk1 substrate required for proper spindle orientation and mitotic progression.

Zhu M, Settele F, Kotak S, Sanchez-Pulido L, Ehret L, Ponting CP, Gönczy P, Hoffmann I.

J Cell Biol. 2013 Mar 18;200(6):773-87. doi: 10.1083/jcb.201207050.

31.

Cortical dynein is critical for proper spindle positioning in human cells.

Kotak S, Busso C, Gönczy P.

J Cell Biol. 2012 Oct 1;199(1):97-110. doi: 10.1083/jcb.201203166.

32.

Longitudinal trends in resource use in an incident cohort of open-angle glaucoma patients: resource use in open-angle glaucoma.

Stein JD, Niziol LM, Musch DC, Lee PP, Kotak SV, Peters CM, Kymes SM.

Am J Ophthalmol. 2012 Sep;154(3):452-459.e2. doi: 10.1016/j.ajo.2012.03.032. Epub 2012 Jul 11.

33.

The development of a decision analytic model of changes in mean deviation in people with glaucoma: the COA model.

Kymes SM, Lambert DL, Lee PP, Musch DC, Siegfried CJ, Kotak SV, Stwalley DL, Fain J, Johnson C, Gordon MO.

Ophthalmology. 2012 Jul;119(7):1367-74. doi: 10.1016/j.ophtha.2012.01.054. Epub 2012 Apr 25.

34.

Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic review.

Reardon G, Kotak S, Schwartz GF.

Patient Prefer Adherence. 2011;5:441-63. doi: 10.2147/PPA.S23780. Epub 2011 Sep 23.

35.

An assessment of the health and economic burdens of glaucoma.

Varma R, Lee PP, Goldberg I, Kotak S.

Am J Ophthalmol. 2011 Oct;152(4):515-22. doi: 10.1016/j.ajo.2011.06.004. Review.

37.

A multicenter, retrospective chart review study comparing index therapy change rates in open-angle glaucoma or ocular hypertension patients newly treated with latanoprost or travoprost-Z monotherapy.

Fain JM, Kotak S, Mardekian J, Bacharach J, Edward DP, Rauchman S, Brevetti T, Fox JL, Lovelace C.

BMC Ophthalmol. 2011 Jun 13;11:13. doi: 10.1186/1471-2415-11-13.

38.

Effect of patient-centered communication training on discussion and detection of nonadherence in glaucoma.

Hahn SR, Friedman DS, Quigley HA, Kotak S, Kim E, Onofrey M, Eagan C, Mardekian J.

Ophthalmology. 2010 Jul;117(7):1339-47.e6. doi: 10.1016/j.ophtha.2009.11.026. Epub 2010 Mar 7.

PMID:
20207417
39.

Persistence on prostaglandin ocular hypotensive therapy: an assessment using medication possession and days covered on therapy.

Reardon G, Schwartz GF, Kotak S.

BMC Ophthalmol. 2010 Mar 2;10:5. doi: 10.1186/1471-2415-10-5.

40.

Physicians' treatment decisions, patient persistence, and interruptions in the continuous use of prostaglandin therapy in glaucoma.

Hahn SR, Kotak S, Tan J, Kim E.

Curr Med Res Opin. 2010 Apr;26(4):957-63. doi: 10.1185/03007991003659012.

PMID:
20163296
41.

Hyperemia-associated costs of medication changes in glaucoma patients treated initially with prostaglandin analogs.

Schwartz GF, Tan J, Kotak S.

J Ocul Pharmacol Ther. 2009 Dec;25(6):555-61. doi: 10.1089/jop.2009.0057.

PMID:
20028264
42.

Doctor-patient communication in glaucoma care: analysis of videotaped encounters in community-based office practice.

Friedman DS, Hahn SR, Quigley HA, Kotak S, Kim E, Onofrey M, Eagan C, Mardekian J.

Ophthalmology. 2009 Dec;116(12):2277-85.e1-3. doi: 10.1016/j.ophtha.2009.04.052. Epub 2009 Sep 10.

PMID:
19744715
43.

Complexity of the heat stress response in plants.

Kotak S, Larkindale J, Lee U, von Koskull-Döring P, Vierling E, Scharf KD.

Curr Opin Plant Biol. 2007 Jun;10(3):310-6. Epub 2007 May 4. Review.

PMID:
17482504
44.

A novel transcriptional cascade regulating expression of heat stress proteins during seed development of Arabidopsis.

Kotak S, Vierling E, Bäumlein H, von Koskull-Döring P.

Plant Cell. 2007 Jan;19(1):182-95. Epub 2007 Jan 12.

45.

A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma.

Lee PP, Walt JG, Doyle JJ, Kotak SV, Evans SJ, Budenz DL, Chen PP, Coleman AL, Feldman RM, Jampel HD, Katz LJ, Mills RP, Myers JS, Noecker RJ, Piltz-Seymour JR, Ritch RR, Schacknow PN, Serle JB, Trick GL.

Arch Ophthalmol. 2006 Jan;124(1):12-9.

PMID:
16401779
46.

Direct costs of glaucoma and severity of the disease: a multinational long term study of resource utilisation in Europe.

Traverso CE, Walt JG, Kelly SP, Hommer AH, Bron AM, Denis P, Nordmann JP, Renard JP, Bayer A, Grehn F, Pfeiffer N, Cedrone C, Gandolfi S, Orzalesi N, Nucci C, Rossetti L, Azuara-Blanco A, Bagnis A, Hitchings R, Salmon JF, Bricola G, Buchholz PM, Kotak SV, Katz LM, Siegartel LR, Doyle JJ.

Br J Ophthalmol. 2005 Oct;89(10):1245-9.

47.

Heat stress response in plants: a complex game with chaperones and more than twenty heat stress transcription factors.

Baniwal SK, Bharti K, Chan KY, Fauth M, Ganguli A, Kotak S, Mishra SK, Nover L, Port M, Scharf KD, Tripp J, Weber C, Zielinski D, von Koskull-Döring P.

J Biosci. 2004 Dec;29(4):471-87. Review.

PMID:
15625403
49.

Splenic Hæmorrhage.

Kotak SJ.

Ind Med Gaz. 1901 Dec;36(12):456-457. No abstract available.

Supplemental Content

Support Center